NCT06540144View on ClinicalTrials.gov

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

August 17, 2027

Study Completion Date

August 17, 2027

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

rozanolixizumab

rozanolixizumab solution for injection

Trial Locations (6)

Unknown

Mg0008 40290, Bologna

Mg0008 40144, Milan

Mg0008 40734, Lodz

Mg0008 40155, Warsaw

Mg0008 20081, Taipei

Mg0008 20095, Taipei

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY